Clin2
NCT07668739Possibly a fitNot yet recruiting

Testing vericiguat for heart failure and tricuspid valve leak

HFrEFTricuspid Regurgitation (TR)

Treatments studied

Part of Heart & circulation clinical trials.

This trial tests a drug called vericiguat to see if it helps people with heart failure affecting the right side of the heart and a leaky tricuspid valve. You may qualify if you have a weak right ventricle, a low pump strength in the left ventricle, and symptoms that have recently gotten worse.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
100 people
Ages
19 years and older
Study type
Interventional

Who can take part

  • You are 19 years or older.
  • Your heart's right ventricle is weak, confirmed by an EKG or MRI.
  • You have chronic heart failure with a pumping strength (ejection fraction) below 45%.
  • You have been on standard heart failure treatment for at least 4 weeks.
  • You have high NT-proBNP levels (a sign of heart strain) or have recently needed treatment for worsening heart failure.
  • You have at least moderate tricuspid regurgitation (leaky right heart valve).
  • You have not taken vericiguat in the last 6 months.
  • Your systolic blood pressure is 100 mmHg or higher.
  • You are not currently taking other similar heart medications (like sildenafil or riociguat).
  • Your right ventricle failure does not require surgery.
  • You are not pregnant and are not of childbearing potential without using birth control.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06877520Recruiting
Study of a new device for fixing leaky tricuspid valve

This trial tests a new, less-invasive device called 'Pivot Extend' for people with a severe leaky tricuspid valve (tricuspid regurgitation) who still have symptoms despite taking medicines. The goal is to see if the device can safely help reduce the leak and improve symptoms.

Tbilisi, K'alak'i T'bilisi
NCT07578129Not yet recruiting
Heart valve repair registry for advanced heart failure

This study tracks patients with weak heart pumps and leaky tricuspid valves (a valve on the right side of the heart) who receive a minimally invasive repair procedure. The goal is to understand how this treatment affects patients' heart function and quality of life over time.

NCT07405944Recruiting· Phase 4
Vericiguat and heart function in heart failure patients

This trial tests whether vericiguat can improve heart function in people with stable heart failure and a reduced pumping ability. It may help if you have not needed hospital or IV treatments for worsening heart failure in the last 6 months.

Ljubljana
NCT06717204Not yet recruiting
Vericiguat for heart failure after a heart attack

This trial tests a medication called Vericiguat for people with heart failure and a weak heart pump after a past heart attack. It aims to see if the drug can help improve your condition.

Jinan, Shandong
NCT07697833Not yet recruiting· Phase 4
Comparing vericiguat with standard care for heart failure

This trial tests a new medicine called vericiguat against standard treatments to see if it helps people with worsening heart failure. It may be an option if you have heart failure with a weak heart pump and recently needed more medical help.

NCT07444398Recruiting· Phase 1
Vericiguat for worsening heart failure

This trial tests if adding vericiguat to standard heart failure medicines helps people hospitalized with worsening heart failure. It's for those with a weak heart pump and high NT-proBNP levels.

Rawalpindi, Punjab Province

Hear when a new HFrEF trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.